Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
J Med Chem ; 63(7): 3577-3595, 2020 04 09.
Article in English | MEDLINE | ID: mdl-32141297

ABSTRACT

Free fatty acid receptor 3 (FFA3, previously GPR41) is activated by short-chain fatty acids, mediates health effects of the gut microbiota, and is a therapeutic target for metabolic and inflammatory diseases. The shortage of well-characterized tool compounds has however impeded progress. Herein, we report structure-activity relationship of an allosteric modulator series and characterization of physicochemical and pharmacokinetic properties of selected compounds, including previous and new tools. Two representatives, 57 (TUG-1907) and 63 (TUG-2015), showed improved solubility and preserved potency. Of these, 57, with EC50 = 145 nM and a solubility of 33 µM, showed high clearance in vivo but is a preferred tool in vitro. In contrast, 63, with EC50 = 162 nM and a solubility of 9 µM, showed lower clearance and seems better suited for in vivo studies. Using 57, we demonstrate for the first time that FFA3 activation leads to calcium mobilization in murine dorsal root ganglia.


Subject(s)
Quinolones/pharmacology , Receptors, G-Protein-Coupled/metabolism , Allosteric Regulation , Animals , Drug Stability , Ganglia, Spinal/drug effects , Humans , Mice, Knockout , Microsomes, Liver/metabolism , Molecular Docking Simulation , Molecular Structure , Quinolones/chemical synthesis , Quinolones/metabolism , Quinolones/pharmacokinetics , Receptors, G-Protein-Coupled/genetics , Structure-Activity Relationship
2.
Sci Rep ; 8(1): 10010, 2018 07 03.
Article in English | MEDLINE | ID: mdl-29968758

ABSTRACT

The succinate receptor 1 (SUCNR1) is a receptor for the metabolite succinate, which functions as a metabolic stress signal in the liver, kidney, adipose tissue and the retina. However, potent non-metabolite tool compounds are needed to reveal the physiological role and pharmacological potential of SUCNR1. Recently, we published the discovery of a computationally receptor-structure derived non-metabolite SUCNR1 agonist series with high target selectivity. We here report our structure-activity exploration and optimisation that has resulted in the development of agonists with nanomolar potency and excellent solubility and stability properties in a number of in vitro assays. Ligand-guided receptor models with high discriminative power between binding of active and inactive compounds were developed for design of novel chemotypes.


Subject(s)
Receptors, G-Protein-Coupled/agonists , Receptors, Purinergic P2Y1/metabolism , Structure-Activity Relationship , Animals , Crystallography, X-Ray , Humans , Mice , Receptors, G-Protein-Coupled/metabolism , Receptors, Purinergic P2Y1/ultrastructure , Succinic Acid/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...